Ataluren for the treatment of cystic fibrosis

References

• Rowe SM, Miller S. Sorscher EJ cystic fibrosis. N Engl J Med. 2005;352:1992–2001.
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al., PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91.
   PubMed Web of Science ®Google Scholar
• Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008;105:2064–2069.
   PubMed Web of Science ®Google Scholar
• Linde L, Kerem B, Nonsense-mediated mRNA decay and cystic fibrosis. Methods Mol Biol. 2011;741:137–154.
   PubMedGoogle Scholar
• Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations ñ correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575–606.
   PubMed Web of Science ®Google Scholar
• Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test. 1997;1(1):35–39.
   PubMedGoogle Scholar
• Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50(1):222–228.
   PubMed Web of Science ®Google Scholar
• de Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60(7):558–563.
   PubMed Web of Science ®Google Scholar
• CF Foundation. Patients registry 2012. Available from: http://www.cysticfibrosisdata.org/ReportsUS.html file:///C:/Documents%20and%20Settings/shoseyov/My%20Documents/Downloads/2012-CFF-Patient-Registry.pdf
   Google Scholar
• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–1080.
   PubMed Web of Science ®Google Scholar
• Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–1065.
   PubMed Web of Science ®Google Scholar
• Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68:809–819.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride analysis with classes of CFTR gene mutations. J Pediatr. 1995;127:705–710.
   PubMed Web of Science ®Google Scholar
• Howard M, Frizzell RA, Bedwell DM, Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2:467–469.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Bebök Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163:1683–1692.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y, et al., Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433–1441.
   PubMed Web of Science ®Google Scholar
• Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest. 2007;117:683–692.
   PubMed Web of Science ®Google Scholar
• Mort M, Ivanov D, Cooper DN, et al. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008;29:1037–1047.
   PubMed Web of Science ®Google Scholar
• Celik A, Kervestin S, Jacobson A. NMD: at the crossroads between translation termination and ribosome recycling. Biochimie. 2015;114:2–9.
   PubMed Web of Science ®Google Scholar
• Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Biol. 2012;13:700–712.
   PubMed Web of Science ®Google Scholar
• Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem. 2010;18:3735–3746.
   PubMed Web of Science ®Google Scholar
• Xue X, Mutyam V, Tang L, et al., Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol. 2014;50:805–816.
   PubMed Web of Science ®Google Scholar
• Lentini L, Melfi R, Di Leonardo A, et al. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol Pharm. 2014;11(3):653–664.
   PubMed Web of Science ®Google Scholar
• McElroy SP, Nomura T, Torrie LS, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol. 2013;11:e1001593.
   PubMed Web of Science ®Google Scholar
• Bidou L, Allamand V, Rousset JP, et al. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med. 2012;18:679–688.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Hilarion S, Beghyn T, Jia J, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012;31:58.
   Web of Science ®Google Scholar
• Ryan NJ. Ataluren: first global approval. Drugs. 2014;74:1709–1714.
   PubMed Web of Science ®Google Scholar
• Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47:430–444.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;15(182):1262–1272.
   Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;30:719–727.
   Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38:59–69.
   PubMed Web of Science ®Google Scholar
• Kerem E, Konstan MW, De Boeck K, et al. cystic fibrosis ataluren study group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2:539–547.
   PubMed Web of Science ®Google Scholar
• Kotha K, Clancy JP. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Ther Adv Respir Dis. 2013;7:288–296.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev. 2013;22:66–71.
   PubMedGoogle Scholar